<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017116</url>
  </required_header>
  <id_info>
    <org_study_id>RBHB1103-HK</org_study_id>
    <nct_id>NCT05017116</nct_id>
  </id_info>
  <brief_title>A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Ribo Life Science Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Ribo Life Science Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose&#xD;
      (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and&#xD;
      preliminary pharmacodynamics (PD) of RBD1016 in subjects with chronic HBV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts. Part A is the single dose escalation study where subjects&#xD;
      with chronic HBV infection will be assigned to receive single dose of RBD1016 or placebo .&#xD;
      Part B is the multiple dose escalation study where subjects with chronic HBV infection will&#xD;
      be assigned to receive two doses of RBD1016 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs) within 28 days after treatment (Part A)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>All reported AE terms will be coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA).AEs and SAEs occurred throughout the course of the study will be evaluated and graded based on NCI-CTCAE V5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs) within 28 days after the last treatment(Part B)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>All reported AE terms will be coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA).AEs and SAEs occurred throughout the course of the study will be evaluated and graded based on NCI-CTCAE V5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBsAg dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B surface antigen (HBsAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBsAb dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B surface antibody (HBsAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBeAg dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B e antigen (HBeAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBeAb dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B e antibody (HBeAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBcAb dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B core antibody (HBcAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBcrAg dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B core-related antigen (HBcrAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBV DNA dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PCR will be used to detect HBV DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBV RNA dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PCR will be used to detect HBV RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of peripheral blood T lymphocyte subsets dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Flow Cytometry will be used to detect peripheral blood T lymphocyte subsets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of B cell dynamic changes from baseline to Week 24 (Part A).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Flow Cytometry will be used to detect B cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Cmax (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>PCR will be ued to detect Maximum concentration (Cmax) and PhoenixWinNonlin software (V8.0 or higher) will be used to calculate the PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Tmax (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Time to maximum concentration (Tmax) will be calculated by PhoenixWinNonlin software (V8.0 or higher) will be used to calculate the PK parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter AUC0-t (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Area under the concentration-time curve from 0 to the collection time t (AUC0-t) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter AUC0-inf (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Area under the concentration-time curve from 0 to infinity (AUC0-inf) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter t1/2 (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Half-Life (t1/2) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Vd (Part A).</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Apparent volume of distribution (Vd) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter CL/F (Part A)</measure>
    <time_frame>up to 85 days</time_frame>
    <description>Clearance (CL/F) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBsAg dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B surface antigen (HBsAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBsAb dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B surface antibody (HBsAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBeAg dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B e antigen (HBeAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBeAb dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B e antibody (HBeAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBcAb dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B core antibody (HBcAb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBcrAg dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Electro chmiluminescence method will be used to detect hepatitis B core-related antigen (HBcrAg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBV DNA dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PCR will be used to detect HBV DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of HBV RNA dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PCR will be used to detect HBV RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of peripheral blood T lymphocyte subsets dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Flow Cytometry will be used to detect peripheral blood T lymphocyte subsets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To draw the figure of B cell dynamic changes from baseline to Week 24 (Part B).</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Flow Cytometry will be used to detect B cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Cmax (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>PCR will be ued to detect Maximum concentration (Cmax) and PhoenixWinNonlin software (V8.0 or higher) will be used to calculate the PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Tmax (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Time to maximum concentration (Tmax) will be calculated by PhoenixWinNonlin software (V8.0 or higher) will be used to calculate the PK parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter AUC0-t (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Area under the concentration-time curve from 0 to the collection time t (AUC0-t) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter AUC0-inf (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Area under the concentration-time curve from 0 to infinity (AUC0-inf) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter t1/2 (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Half-Life (t1/2) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter Vd (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Apparent volume of distribution (Vd) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic parameter CL/F (Part B).</measure>
    <time_frame>up to 113 days</time_frame>
    <description>Clearance (CL/F) will be calculated by PhoenixWinNonlin software (V8.0 or higher).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Part A，single dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, multiple dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBD1016</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Part A，single dose group</arm_group_label>
    <arm_group_label>Part B, multiple dose group</arm_group_label>
    <other_name>RBD1016 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Part A，single dose group</arm_group_label>
    <arm_group_label>Part B, multiple dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Take orally.</description>
    <arm_group_label>Part A，single dose group</arm_group_label>
    <arm_group_label>Part B, multiple dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily participate in this clinical trial, are able to correctly&#xD;
             understand and have signed the informed consent in writing;&#xD;
&#xD;
          2. Male or female volunteer aged 18-55 years (inclusive);&#xD;
&#xD;
          3. Body Mass Index (BMI) of 18-30 kg/m2 (inclusive);&#xD;
&#xD;
          4. Subjects with chronic HBV infection, including immunotolerant subjects, treatment&#xD;
             naïve subjects and treated subjects.&#xD;
&#xD;
          5. Ability to cooperate with study staff and comply with the study requirements and&#xD;
             follow the protocol-specified procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with liver diseases other than hepatitis B, including hepatitis C,&#xD;
             hemochromatosis, primary sclerosing cholangitis; alcoholic, drug-related or autoimmune&#xD;
             liver diseases; primary liver cancer and indeterminate nodules on liver imaging test;&#xD;
&#xD;
          2. A history or manifestations of liver decompensation (e.g. Child-Pugh Class B or C, or&#xD;
             ascites, gastrointestinal bleeding, hepatic encephalopathy or spontaneous bacterial&#xD;
             peritonitis, etc.);&#xD;
&#xD;
          3. Transient elastography at screening revealing FibroScan value ≥ 9 kPa or liver biopsy&#xD;
             evidencing hepatic fibrosis within 24 months;&#xD;
&#xD;
          4. The following laboratory findings: total serum bilirubin&gt; 2×ULN; serum&#xD;
             alpha-fetoprotein&gt;50μg/L; serum albumin &lt;3.5g/dL; international normalized ratio&#xD;
             (INR)&gt; 1.25; serum creatinine &gt; 1.5×ULN; any laboratory outliers of clinical&#xD;
             significance that in the investigator's opinion may interfere with the interpretation&#xD;
             of efficacy or safety data;&#xD;
&#xD;
          5. 12-lead ECG abnormalities with clinical significance;&#xD;
&#xD;
          6. Pregnant or lactating women or women of child-bearing potential who are unwilling to&#xD;
             take effective contraception throughout the course of the study (refer to Appendix 3&#xD;
             for details);&#xD;
&#xD;
          7. Other factors that in the investigator's opinion would make it inappropriate for the&#xD;
             subject to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Seto</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHB</keyword>
  <keyword>chronic hepatitis B infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

